| Literature DB >> 34669152 |
Abstract
PURPOSE: Coronavirus Disease 2019 (COVID-19) severity and Diabetes mellitus affect each other bidirectionally. However, the cause of severe acute respiratory syndrome coronavirus 2 (SARS-CoV2) infection on the incidence of diabetes is unclear. In the SARS-CoV-2-infected cells, host microRNAs (miRNAs) may target the native gene transcripts as well as the viral genomic and subgenomic RNAs. Here, we investigated the role of miRNAs in linking Diabetes to SARS-CoV-2 infection in the human pancreas.Entities:
Keywords: COVID-19; Diabetes mellitus; Gene–gene interaction; Minimum Free Energy; SARS-CoV-2; miRNAs
Mesh:
Substances:
Year: 2021 PMID: 34669152 PMCID: PMC8527307 DOI: 10.1007/s40618-021-01693-3
Source DB: PubMed Journal: J Endocrinol Invest ISSN: 0391-4097 Impact factor: 5.467
DEGs between mock-infected and SARS-CoV-2-infected hESC pancreatic organoids
| S. No | Gene symbol | Gene description | Log2FoldChange |
|---|---|---|---|
| 1 | CP | Ceruloplasmin | 3.218646021 |
| 2 | SOCS3 | Suppressor of cytokine signaling 3 | 2.897737916 |
| 3 | VNN3 | Vanin 3 | 2.676974204 |
| 4 | CEBPD | CCAAT enhancer binding protein delta | 2.041519486 |
| 5 | FAM169B | Family with sequence similarity 169 member B | 1.887720767 |
| 6 | VNN2 | Vanin 2 | 1.650151224 |
| 7 | HPX | Hemopexin | 1.576405664 |
| 8 | EVA1A | Eva-1 homolog A, regulator of programmed cell death | 1.483037767 |
| 9 | SERTM1 | Serine rich and transmembrane domain containing 1 | 1.482242018 |
| 10 | CXCL2 | C-X-C motif chemokine ligand 2 | 1.464664038 |
| 11 | C8B | Complement C8 beta chain | 1.45102627 |
| 12 | CFB | Complement factor B | 1.449773368 |
| 13 | SERPINA3 | Serpin family A member 3 | 1.282619509 |
| 14 | TACR1 | Tachykinin receptor 1 | 1.253706268 |
| 15 | HCP5 | HLA complex P5 | 1.228387286 |
| 16 | CHRD | Chordin | 1.226960717 |
| 17 | GADD45G | Growth arrest and DNA damage inducible gamma | 1.223936929 |
| 18 | APOL6 | Apolipoprotein L6 | 1.164596924 |
| 19 | SAMD11 | Sterile alpha motif domain containing 11 | 1.129551911 |
| 20 | AGT | Angiotensinogen | 1.106392771 |
| 21 | C9orf16 | Chromosome 9 open reading frame 16 | 1.096117015 |
| 22 | NLRC5 | NLR family CARD domain containing 5 | 1.094272111 |
| 23 | SUCNR1 | Succinate receptor 1 | 1.067266654 |
| 24 | PSMB8 | Proteasome 20S subunit beta 8 | 1.031089013 |
| 25 | UNC5CL | Unc-5 family C-terminal like | 1.015471709 |
| 26 | MAP6D1 | MAP6 domain containing 1 | 1.000047502 |
| 27 | AKR1B10a | Aldo–Keto Reductase Family 1 member B10 | − 1.942847572 |
| 28 | SYNDIG1La | Synapse differentiation inducing 1 like | − 1.628255609 |
| 29 | PKHD1L1a | Polycystic kidney and hepatic disease 1 like 1 | − 1.414217069 |
| 30 | TMEM236a | Transmembrane protein 236 | − 1.040226661 |
aGenes downregulated in SARS-CoV-2-infected hESC pancreatic organoids
Fig. 1a Volcano plot showing the significant DEGs between mock-infected and SARS-CoV-2-infected hESC pancreatic organoids. Differentially expressed genes with padj < 0.05 and |log2FC|> 1 are shown in red dots b GGI network between the DEGs: Diabetes-associated (Type 1 Diabetes and insulin-associated) DEGs are connected directly or indirectly through co-expression c Diabetes-associated gene targets of the miRNAs that can target the SARS-CoV-2 genome and the Diabetes-associated gene: The circular nodes depict the Diabetes-associated genes. The elliptical nodes represent the miRNAs that can target the 3ʹUTR of the SARS-CoV-2 genome and the Diabetes-associated genes. The rectangular nodes represent the miRNAs that can target the 5ʹUTR of the SARS-CoV-2 genome and the Diabetes-associated genes
Gene-based disease enrichment of DEGs
| S. No | Disease term | Genes |
|---|---|---|
| 1 | Type 1 diabetes | SOCS3, AGTa, CPa, PSMB8 |
| 2 | Alzheimer’s disease, Parkinson’s disease, insulin, lung function, depression, longevity | CFBa, CPa |
| 3 | Cerebrovascular disease | AGTa, SERPINA3a |
| 4 | Respiratory syncytial virus bronchiolitis, asthma, bronchiolitis | SOCS3, CXCL2a, PSMB8 |
| 5 | Birth weight, leukemia, acute myeloid leukemia, precursor cell lymphoblastic leukemia-lymphoma, meningeal neoplasms, meningioma, non-hodgkin’s lymphoma | C8Ba, SOCS3, CFBa |
| 6 | Nephropathy | AGTa, AKR1B10a |
| 7 | Myocardial Infarction | EVA1A, AGTa, GADD45G, SERPINA3a |
| 8 | Plasma HDL cholesterol (HDL-C) levels | SOCS3, CEBPD, AGTa |
| 9 | Macular degeneration | C8Ba, CFBa, SERPINA3a |
aGenes encoding for secretory proteins
Topological parameters of the gene nodes in GGI network (in descending order of Closeness Centrality)
| S. No | Gene name | Degree | Closeness Centrality | Betweenness Centrality |
|---|---|---|---|---|
| 1 | SUCNR1 | 1 | 1 | 0 |
| 2 | TACR1 | 1 | 1 | 0 |
| 3 | CPb | 11 | 0.65625 | 0.334650416 |
| 4 | SERPINA3 | 9 | 0.6 | 0.078909675 |
| 5 | CFBb | 10 | 0.567567568 | 0.124459562 |
| 6 | C8B | 8 | 0.538461538 | 0.124801587 |
| 7 | EVA1A | 7 | 0.525 | 0.007420635 |
| 8 | VNN3 | 6 | 0.525 | 0.055616024 |
| 9 | VNN2 | 6 | 0.525 | 0.25037037 |
| 10 | AGTb | 7 | 0.512195122 | 0.062619048 |
| 11 | CXCL2 | 8 | 0.512195122 | 0.101135676 |
| 12 | HPX | 6 | 0.5 | 0 |
| 13 | CHRD | 3 | 0.446808511 | 0.034950869 |
| 14 | APOL6 | 2 | 0.4375 | 0.096216931 |
| 15 | GADD45G | 4 | 0.4375 | 0.022896825 |
| 16 | PKHD1L1 | 1 | 0.403846154 | 0 |
| 17 | SOCS3b | 3 | 0.396226415 | 0.007539683 |
| 18 | UNC5CL | 2 | 0.381818182 | 0.002380952 |
| 19 | FAM169B | 2 | 0.375 | 0.07521164 |
| 20 | CEBPD | 3 | 0.368421053 | 0.002380952 |
| 21 | AKR1B10 | 1 | 0.355932203 | 0 |
| 22 | SAMD11 | 1 | 0.35 | 0 |
| 23 | PSMB8b | 2 | 0.328125 | 0.023994709 |
| 24 | NLRC5 | 2 | 0.291666667 | 0.013492063 |
| 25 | C9orf16a | 0 | 0 | 0 |
| 26 | TMEM236a | 0 | 0 | 0 |
| 27 | SYNDIG1La | 0 | 0 | 0 |
| 28 | SERTM1a | 0 | 0 | 0 |
| 29 | MAP6D1a | 0 | 0 | 0 |
aSingle node in the network
bDifferentially expressed genes associated with diabetes
miRNAs potentially targeting the viral genome, i.e., CoV-tar-miRNAs
| S. No | 5ʹUTR CoV-tar-miRNAs | 3ʹUTR CoV-tar-miRNAs |
|---|---|---|
| 1 | hsa-miR-298 | hsa-miR-3941 |
| 2 | hsa-miR-7851-3p | hsa-miR-466 |
| 3 | hsa-miR-1303 | hsa-miR-4775 |
| 4 | hsa-miR-3925-5p | hsa-miR-4717-3p |
| 5 | hsa-miR-8075 | hsa-miR-5088-5p |
| 6 | hsa-miR-4691-3p | hsa-miR-603 |
| 7 | hsa-miR-1283 | hsa-miR-6749-3p |
| 8 | hsa-miR-3123 | hsa-miR-1236-3p |
| 9 | hsa-miR-5196-5p | hsa-miR-4279 |
| 10 | hsa-miR-4747-5p | hsa-miR-4672 |
| 11 | hsa-miR-4645-3p |
microRNAs potentially targeting the Diabetes-associated DEGs and SARS-CoV-2 genome
| S. No | Diabetes-associated DEGs | SARS-CoV-2 genome’s region targeted by CoV-tar-miRNAs | CoV-tar-miRNAs targeting the DEGs |
|---|---|---|---|
| 1 | CP | 3ʹUTR | hsa-miR-466a hsa-miR-4775b |
| 5ʹUTR | hsa-miR-3123a hsa-miR-4691-3pb hsa-miR-4747-5pb hsa-miR-5196-5pb | ||
| 2 | SOCS3 | 3ʹUTR | hsa-miR-1236-3pb hsa-miR-3941b hsa-miR-4279b hsa-miR-4717-3pb hsa-miR-5088-5pb hsa-miR-6749-3pa |
| 5ʹUTR | hsa-miR-1303b hsa-miR-3123a hsa-miR-3925-5pb hsa-miR-4691-3pb hsa-miR-7851-3pa | ||
| 3 | AGT | 3ʹUTR | hsa-miR-4775b |
| 5ʹUTR | hsa-miR-1303b hsa-miR-298b hsa-miR-4645-3pb hsa-miR-7851-3pa | ||
| 4 | PSMB8 | 3ʹUTR | hsa-miR-1236-3pb hsa-miR-4279b hsa-miR-5088-5p |
| 5ʹUTR | hsa-miR-298b hsa-miR-3123a hsa-miR-3925-5pb | ||
| 5 | CFB | 3ʹUTR | hsa-miR-4775b |
aUnknown expression of miRNA in the human pancreas tissue
bExpressed in the human pancreas[42, 44, 47]
Minimum Free Energy (MFE) of CoV-tar-miRNAs with the SARS-CoV-2 UTRs and Diabetes-associated host cell’s mRNA targets
| 3ʹUTR CoV-tar-miRNAs | MFE (kcal/mol) of miRNAs with 3ʹUTR of viral genome | Diabetes-associated host cell’s mRNA targets of CoV-tar-miRNAs | MFE (kcal/mol) of miRNAs with 3ʹUTR of host cell’s mRNA targets |
|---|---|---|---|
| hsa-miR-3941 | − 19.2 | SOCS3 | − 24.1 |
| hsa-miR-466 | − 14.7 | CP | − 16.2 |
| hsa-miR-4775 | − 15.7 | CP | − 17.3 |
| AGT | − 19.0 | ||
| CFB | − 18.7 | ||
| hsa-miR-4717-3p | − 26.3 | SOCS3 | − 32.0 |
| hsa-miR-5088-5p | − 21.8 | SOCS3 | − 34.6 |
| PSMB8 | − 26.0 | ||
| hsa-miR-6749-3p | − 21.4 | SOCS3 | − 35.6 |
| hsa-miR-1236-3p | − 24.5 | SOCS3 | − 34.7 |
| PSMB8 | − 25.7 | ||
| hsa-miR-4279 | − 19.3 | SOCS3 | − 31.8 |
| PSMB8 | − 23.1 | ||
| 5ʹUTR CoV-tar-miRNAs | MFE of miRNAs with 5ʹUTR of viral genome | ||
| hsa-miR-298a | − 24.8 | AGT | − 28.3 |
| PSMB8a | − 24.7 | ||
| hsa-miR-7851-3p | − 26.7 | SOCS3 | − 30.7 |
| AGT | − 29.0 | ||
| hsa-miR-1303 | − 21.0 | SOCS3 | − 29.9 |
| AGT | − 25.5 | ||
| hsa-miR-3925-5pa | − 24.2 | SOCS3a | − 22.9 |
| PSMB8a | − 22.4 | ||
| hsa-miR-4691-3pa | − 25.5 | CPa | − 20.7 |
| SOCS3 | − 32.1 | ||
| hsa-miR-3123 | − 14.7 | CP | − 15.8 |
| SOCS3 | − 17.0 | ||
| PSMB8 | − 15.4 | ||
| hsa-miR-5196-5pa | − 29.6 | CPa | − 25.6 |
| hsa-miR-4747-5p | − 21.3 | CP | − 24.2 |
| hsa-miR-4645-3p | − 20.9 | AGT | − 29.0 |
aCoV-tar-miRNAs showing higher MFE with Diabetes-associated mRNA targets than with SARS-CoV-2 genome UTR
Fig. 2Differential targeting of the host cell’s native miRNAs: a The cell’s native miRNAs regulate the genes by only targeting and suppressing the cell’s native mRNAs. b In a SARS-CoV-2-infected cell, the viral + ssRNA genome copies compete with the host cell’s native mRNAs in being targeted by the native miRNAs. The host miRNAs get apportioned in targeting the SARS-CoV-2 genome copies too. It reduces the contribution of miRNAs in regulating the host cell’s genes, thus, upregulating them